US 12,486,512 B2
Solute carrier family member iRNA compositions and methods of use thereof
Lucas D. Ward, Cambridge, MA (US); Ho-Chou Tu, Cambridge, MA (US); James D. McIninch, Cambridge, MA (US); and Paul Nioi, Cambridge, MA (US)
Assigned to Alnylam Pharmaceuticals, Inc., Cambridge, MA (US)
Appl. No. 17/768,914
Filed by Alnylam Pharmaceuticals, Inc., Cambridge, MA (US)
PCT Filed Oct. 16, 2020, PCT No. PCT/US2020/055877
§ 371(c)(1), (2) Date Apr. 14, 2022,
PCT Pub. No. WO2021/076828, PCT Pub. Date Apr. 22, 2021.
Claims priority of provisional application 62/916,996, filed on Oct. 18, 2019.
Claims priority of provisional application 62/916,993, filed on Oct. 18, 2019.
Prior Publication US 2024/0141358 A1, May 2, 2024
Int. Cl. C12N 15/11 (2006.01); C12N 15/113 (2010.01)
CPC C12N 15/1138 (2013.01) [C12N 2310/14 (2013.01); C12N 2310/351 (2013.01)] 21 Claims
 
1. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of solute carrier family 39 member 8 (SLC39A8) in a cell, or a salt thereof,
wherein the dsRNA agent, or a salt thereof, comprises a sense strand and an antisense strand forming a double stranded region,
wherein the antisense strand comprises at least 19 contiguous nucleotides from any one of the antisense strand nucleotide sequences selected from the group consisting of
5′-UGAGAAACCAUGAAGAGAAAAGA-3′ of SEQ ID NO: 1465;
5′-UAACCAUGAAGAGAAAAGAUGUC-3′ of SEQ ID NO:1468;
5′-UCAUGAAGAGAAAAGAUGUCUUC-3′ of SEQ ID NO:1471;
5′-UCCAUGAAGAGAAAAGAUGUCUU-3′ of SEQ ID NO:1470;
5′-UGAAACCAUGAAGAGAAAAGAUG-3′ of SEQ ID NO:1476; and
5′-UACCAUGAAGAGAAAAGAUGUCU-3′ of SEQ ID NO:1477,
wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a nucleotide modification, and
wherein at least one strand is conjugated to a ligand.